Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 310 | 28% |
| 2020 | 8 | 299 | 30% |
| 2021 | 11 | 345 | 32% |
| 2022 | 12 | 421 | 35% |
| 2023 | 10 | 401 | 38% |
| 2024 | 13 | 456 | 39% |
| 2025 from claims | – | 534 432–627 | 40% |
| 2026 forecast | – | 588 460–738 | 39% |
| 2027 forecast | – | 638 473–844 | 40% |
| 2028 forecast | – | 693 490–956 | 40% |
| 2029 forecast | – | 752 511–1,078 | 40% |
| 2030 forecast | – | 816 535–1,212 | 40% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 89% of the cases CMS names in Massachusetts; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| Forecast, Medicare FFS | Inpatient |
|---|---|
| 2026 · ~590 | ~590 |
| 2027 · ~640 | ~640 |
| 2028 · ~690 | ~690 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 25 | 1,148+12%/yr | +12%/yr | 0.6 | 0% | 1,980 in 2030+9.5%/yr |
| Pennsylvania | 29 | 803+20%/yr | +20%/yr | 0.6 | 0% | 1,470 in 2030+11%/yr |
| New Jersey | 13 | 399+11%/yr | +11%/yr | 0.4 | 0% | 600 in 2030+7.1%/yr |
| Connecticut | 6 | 214+31%/yr | +31%/yr | 0.6 | 0% | 330 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 15 | 351+2.1%/yr | +2.1%/yr | 0.40.8× | 0% | 410 in 2030+2.8%/yr |
| DBS & VNS | 6 | 233−7.5%/yr | −7.5%/yr | 0.20.9× | 0% | 270 in 2030+2.6%/yr |
| CSF shunts | 5 | 193−8.4%/yr | −8.4%/yr | 0.21.0× | 0% | 220 in 2030+1.9%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Microvention leads with 29% of company spending on these surgeons in 2025, −12 pts on 2024.
In 2025, 9 companies reported engagement with Massachusetts’s surgeons worth $266K in consulting, speaking, meals and travel tied to these products, about $20K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.